 Home > Active Ingredient News > Antitumor Therapy > ESMO: Chemotherapy combined with nivolumab for locally advanced resectable NSCLC, the 42-month OS rate was 87.3% (NADIM study)

ESMO: Chemotherapy combined with nivolumab for locally advanced resectable NSCLC, the 42-month OS rate was 87.3% (NADIM study)

 Last Update: 2022-04-23
 Source: Internet
 Author: User

Tags

cancer kills

bulldog clamps surgery

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

The NADIM study is one of the earlier neoadjuvant studies of immunotherapy combined with chemotherapy.
The results of the study announced at the 2018 WCLC Congress showed that chemotherapy combined with immunotherapy in the neoadjuvant stage is effective in locally advanced, potentially resectable NSCLC patients.
showed excellent antitumor efficacy
.

immune NSCLC

NSCLC accounts for 80%–85% of all lung cancer cases, and approximately 20% of NSCLC patients are diagnosed with stage IIIA (N2) disease
.
Even if these patients had surgically resected tumors, the clinical outcomes remained suboptimal: the median progression-free survival (PFS) was 13 months, and the 3-year survival rate was 30%

Lung Cancer Diagnosis

Previous studies have shown that only a small number of patients can achieve complete pathological remission (pCR) after induction chemotherapy, and neoadjuvant immunotherapy is expected to significantly improve the prognosis of patients
.
In 2018, a study reported the efficacy of nivolumab neoadjuvant therapy in NSCLC.

After 2 doses of nivolumab neoadjuvant therapy, 45% of 20 evaluable patients achieved major pathological response (MPR), of which , 10% of patients achieved pCR; a phase II study published in 2020 showed that atezolizumab + chemotherapy for neoadjuvant treatment of patients with resectable NSCLC, 57% of patients achieved MPR, of which, 33% of patients achieved pCR

However, whether neoadjuvant chemotherapy combined with immunotherapy can improve the complete pathological response in patients with resectable stage IIIA NSCLC has not been reported, and it is worth further research
.

The NADIM study (CA209-547, NCT03081689) is a phase II, single-arm, open-label, multicenter study in patients with locally advanced, resectable stage IIIA N2 NSCLC
.
The patient received chemotherapy plus nivolumab followed by adjunctive therapy for 1 year

In 2020, NADIM published its 2-year follow-up results in The Lancet .
Among 46 patients, 26 (56%) achieved pathological complete response (pCR), and the major pathological response rate [MPR (inc pCR)] was 74 %
.

Lancet

On September 24, 2020, the updated follow-up data were published in the journal Lancet Oncology
.
The data showed that all patients underwent R0 resection, and the 12-month PFS rate was 95.

7%, the 18-month PFS rate was 87%, and the 24 -month PFS rate was 77.

On September 24, 2020, the updated follow-up data were published in the journal Lancet Oncology

At WCLC 2021, the NADIM study published data after a median follow-up of 37.

9 months for the entire group of patients

At WCLC 2021, the NADIM study published data after a median follow-up of 37.

leave a message here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.